Advertisement

Topics

Companies Related to "InDex Pharmaceuticals Receives Orphan drug Designation Pediatric Ulcerative" [Most Relevant Company Matches] RSS

08:27 EDT 18th October 2018 | BioPortfolio

Here are the most relevant search results for "InDex Pharmaceuticals Receives Orphan drug Designation Pediatric Ulcerative" found in our extensive corporate database of over 50,000 company records.

Showing "InDex Pharmaceuticals Receives Orphan drug Designation Pediatric Ulcerative" Companies 1–25 of 5,300+

Relevant

Emmaus Life Sciences, Inc.

Emmaus Life Sciences is dedicated to the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease and sickle beta-0 thalassemia was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The therapy has Orphan D...


Santhera Pharmaceuticals Holding Ltd

Santhera Pharmaceuticals is a Swiss biopharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases. Santhera’s vision is to become the leading specialty pharmaceuticals company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indic...

AOP Orphan Pharmaceuticals AG

AOP Orphan is a multinational company with headquarters in Vienna, Austria, focusing on clinical research, development and distribution of medicines for rare and complex diseases. The company also provides individualized and customized services to meet and accommodate the needs of physicians and patients across Europe, the Middle East & Asia. Currently AOP...


AcuityBio Inc. and Cook Biotech Inc.

AcuityBio has developed a platform technology for localized, sustained, safe drug-delivery to be used in the prevention of post-surgical lung cancer recurrence. ABC103 combines approved/ cleared surgical staple-line buttress, drug eluting polymers and a chemotherapeutic drug, paclitaxel). ABC103 has been granted US FDA orphan drug designation for this indi...

S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug ...

Gentium S.p.A.

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan ...

Atlantic Healthcare

Atlantic Healthcare is an international specialty pharmaceutical company focussed on diseases of the gastrointestinal tract and Inflammatory Bowel Disease (IBD). The Company's lead product is alicaforsen enema, in Phase 3 development for pouchitis, and in preparation for Phase 3 clinical development for Ulcerative Colitis. Alicaforsen is also generating ea...

Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is dedicated to alleviating the burden of patients suffering from autoimmune diseases by developing novel immunotherapeutic agents. Immune's lead product candidate, bertilimumab, is in Phase 2 clinical development for bullous pemphigoid, an orphan autoimmune dermatological condition, and for ulcerative colitis. Oth...

Lumos Pharma, Inc.

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and is funded by leading healthcare investors, including Deerfield, NEA, Clarus,...

Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cance...

Maas Biolab LLC

Maas Biolab is a private pharmaceutical company in Albuquerque, N.M., USA, developing Mitogard®, the only cyclosporine formula designed for CSF delivery, to treat amyotrophic lateral sclerosis. Maas Biolab holds FDA Orphan Drug Designation for cyclosporine to treat ALS and world patents for cyclosporine neuroprotection against chronic neurological disea...

Atlantic Healthcare plc

Atlantic Healthcare is an international specialty pharmaceutical company focussed on diseases of the gastrointestinal tract and Inflammatory Bowel Disease (IBD). The Company's lead product is alicaforsen enema, in Phase 3 development for pouchitis, and in preparation for Phase 3 clinical development for Ulcerative Colitis. Alicaforsen is also generating ea...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

China Pediatric Pharmaceuticals, Inc.

China Pediatric Pharmaceuticals, Inc. has its headquarters in Xi’an, Shaanxi Province, China. The Company identifies, discovers, develops manufactures and distributes both prescription and over-the counter, including both conventional and Traditional Chinese Medicines (“TCMs”), pharmaceutical products for the treatment of some of the most common ...

Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. RNA interference is a biological process in which RNA molecules regulate expression of targeted genes. Quark’s fully integrated drug discovery and development platform spans the process from therape...

Children's Mercy Hospitals and Clinics

Children's Mercy Hospitals and Clinics, located in Kansas City, Mo., is one of the nation's top pediatric medical centers. The 314-bed hospital provides care for children from birth through the age of 18, and has been recognized by the American Nurses Credentialing Center with Magnet designation for excellence in nursing services, and ranked by U.S. News & World Report as one of "America's Best Ch...

TRACT Therapeutics, Inc.

TRACT Therapeutics, Inc. is a clinical-stage biotechnology company developing a novel therapeutic approach to restoring immune balance in transplantation and autoimmune disease. It’s proprietary platform technology, using autologous, polyclonally expanded T-regulatory cells was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, P...

EntreMed, Inc.

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and antiinflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. Panzem® (2-methoxyestradiol or 2ME2), one of t...

Orphan Europe (UK) Ltd.

Orphan Europe was started with the objective of providing orphan drugs to patients afflicted by rare disorders.Over the years an information network has been established to increase the awareness about rare disorders among healthcare professionals. The company has committed itself to provide support necessary to those working in this field. This is achieved through an extensive collaboration with ...

Randall Children’s Hospital

Randall Children’s Hospital is one of Oregon’s largest providers of pediatric inpatient and trauma services and is part of Legacy Health’s seven-hospital system. Randall Children’s Hospital opened its new nine-story, 165-bed home in Portland in February 2012. With a medical staff of more than 600 physicians, including pediatric me...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...

The Orthopaedic Institute for Children

Orthopaedic Institute for Children (OIC) was founded in 1911 as Los Angeles Orthopaedic Hospital. Focused solely on musculoskeletal conditions in children, OIC receives 60,000 patient visits each year. In alliance with UCLA Health and with the support of the OIC Foundation, we advance pediatric orthopaedics worldwide through outstanding patient care, medic...

Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat and manage disease. The company's two lead compounds, Zemivaâ„¢ and Azedraâ„¢, are in advancing clinical programs. Molecular Insight has completed a Phase 2b clinical trial for its lead cardio...

Access to Nutrition Index

The 2016 Index concluded that, while some companies have taken positive steps since the last Index, the industry as a whole is moving far too slowly. Scored out of ten on their nutrition-related commitments, practices and levels of disclosure, no company achieved a score of more than 6.4.

Orthopaedic Institute for Children

Orthopaedic Institute for Children (OIC) was founded in 1911 as Los Angeles Orthopaedic Hospital. Focused solely on musculoskeletal conditions in children, Orthopaedic Institute for Children receives 60,000 patient visits each year. In alliance with UCLA Health and with the support of the OIC Foundation, we advance pediatric orthopaedics worldwide through ...


More From BioPortfolio on "InDex Pharmaceuticals Receives Orphan drug Designation Pediatric Ulcerative"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks